Approach to the hypophosphatemic patient

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 3, 2012, Pages 696-706

  Imel, Erik A ^a   Econs, Michael J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ACETAZOLAMIDE; ADEFOVIR; ALKALINE PHOSPHATASE; AMINOGLYCOSIDE DERIVATIVE; ANTACID AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CISPLATIN; CREATININE; FIBROBLAST GROWTH FACTOR 23; IFOSFAMIDE; IMATINIB; IRON; LOOP DIURETIC AGENT; MANNITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; POTASSIUM DIHYDROGEN PHOSPHATE; SEVELAMER; SODIUM DIHYDROGEN PHOSPHATE; SODIUM PHOSPHATE COTRANSPORTER 2A; STREPTOZOCIN; TENOFOVIR; TETRACYCLINE DERIVATIVE; THIAZIDE DIURETIC AGENT; TOLUENE; UNINDEXED DRUG; VITAMIN D;

ALCOHOLISM; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIARRHEA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCIURIA; HYPERVENTILATION; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY CALCIFICATION; KIDNEY DISEASE; KIDNEY FAILURE; LABORATORY TEST; MALABSORPTION; MUTATIONAL ANALYSIS; PATIENT CARE PLANNING; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PHYSICAL EXAMINATION; PREMATURITY; PRIORITY JOURNAL; REFEEDING SYNDROME; RESPIRATORY ALKALOSIS; REVIEW; RISK ASSESSMENT; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY;

AGED; HUMANS; HYPOPHOSPHATEMIA; KIDNEY; MALE; PHOSPHATES;

EID: 84858042043     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1319     Document Type: Review

References (83)

1. Liamis G, Milionis HJ, Elisaf M 2010 Medication-induced hypophosphatemia: a review. QJM 103:449-459
2. Kruse K, Kracht U, Göpfert G 1982 Renal threshold phosphate concentration (TmPO4/GFR). Arch Dis Child 57:217-223 (Pubitemid 12190341)
3. Soldin SJ, Hunt C, Hicks JM 1999 Pediatric reference ranges for phosphorus on the Vitros 500 Analyzer. Clin Chem 45:A22 (abstract)
4. Shiber JR, Mattu A 2002 Serum phosphate abnormalities in the emergency department. J Emerg Med 23:395-400 (Pubitemid 35449754)
5. Laaban JP, Marsal L, Waked M, Vuong TK, Rochemaure J 1990 Seizures related to severe hypophosphataemia induced by mechanical ventilation. Intensive Care Med 16:135-136 (Pubitemid 20277729)
6. Silvis SE, DiBartolomeo AG, Aaker HM 1980 Hypophosphatemia and neurological changes secondary to oral caloric intake: a variant of hyperalimentation syndrome. Am J Gastroenterol 73:215-222 (Pubitemid 10046389)
7. Silvis SE, Paragas Jr PD 1972 Paresthesias, weakness, seizures, and hypophosphatemia in patients receiving hyperalimentation. Gastroenterology 62:513-520
8. Brunelli SM, Goldfarb S 2007 Hypophosphatemia: clinical consequences and management. J Am Soc Nephrol 18:1999-2003 (Pubitemid 47041063)
9. Econs MJ, Samsa GP, Monger M, Drezner MK, Feussner JR 1994 X-linked hypophosphatemic rickets: a disease often unknown to affected patients. Bone Miner 24:17-24 (Pubitemid 24071555)
10. Econs MJ, Feussner JR, Samsa GP, Effman EL, Vogler JB, Martinez S, Friedman NE, Quarles LD, Drezner MK 1991 X-linked hypophosphatemic rickets without "rickets." Skeletal Radiol 20:109- 114
11. Mäkitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E 2003 Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 88:3591-3597 (Pubitemid 37034500)
12. Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, Whyte MP 1989 X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine (Baltimore) 68:336-352 (Pubitemid 19286654)
13. Hyp-Consortium 1995 A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 11:130-136
14. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD 2003 Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419-37426 (Pubitemid 37175262)
15. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T 2006 Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774 (Pubitemid 44949607)
16. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429-435 (Pubitemid 38787398)
17. Farrow EG, Davis SI, Summers LJ, White KE 2009 Initial FGF23- mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 20:955-960
18. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE 2006 Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-1315 (Pubitemid 44646294)
19. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, Manor E, Buriakovsky S, Hadad Y, Goding J, Parvari R 2010 Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86:273-278
20. Lorenz-Depiereux B, Schnabel D, Tiosano D, Häusler G, Strom TM 2010 Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 86:267-272
21. ADHR Consortium 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26: 345-348
22. Bai XY, Miao D, Goltzman D, Karaplis AC 2003 The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843-9849 (Pubitemid 36800487)
23. Imel EA, Hui SL, Econs MJ 2007 FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22:520-526 (Pubitemid 47457428)
24. Econs MJ, McEnery PT 1997 Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82: 674-681 (Pubitemid 27068650)
25. Gribaa M, Younes M, Bouyacoub Y, Korbaa W, Ben Charfeddine I, Touzi M, Adala L, Mamay O, Bergaoui N, Saad A 2010 An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation. J Bone Miner Metab 28:111-115
26. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692 (Pubitemid 38057709)
27. Hoffman WH, Jueppner HW, Deyoung BR, O'dorisio MS, Given KS 2005 Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome. Am J Med Genet A 134:233-236
28. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jan de Beur SM, Mentzel T, Montgomery E, Michal M, Miettinen M, Mills SE, Reith JD, O'Connell JX, Rosenberg AE, Rubin BP, Sweet DE, Vinh TN, Wold LE, Wehrli BM, White KE, Zaino RJ, Weiss SW 2004 Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1-30 (Pubitemid 38031617)
29. Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T 2008 Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients. Proposal of diagnostic criteria using FGF23 measurement. Bone 42:1235- 1239
30. Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ 2006 Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91:2055-2061 (Pubitemid 43854981)
31. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663 (Pubitemid 36459471)
32. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960 (Pubitemid 35316332)
33. Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SM, Jüppner H, Wolf M 2006 Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism?' Kidney Int 70:1486-1494
34. Bergwitz C, Roslin NM, Tieder M, Loredo-Osti JC, Bastepe M, Abu-Zahra H, Frappier D, Burkett K, Carpenter TO, Anderson D, Garabedian M, Sermet I, Fujiwara TM, Morgan K, Tenenhouse HS, Juppner H 2006 SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 78:179-192 (Pubitemid 43157559)
35. Hoopes Jr RR, Raja KM, Koich A, Hueber P, Reid R, Knohl SJ, Scheinman SJ 2004 Evidence for genetic heterogeneity in Dent's disease. Kidney Int 65:1615-1620 (Pubitemid 38591008)
36. Nesterova G, Gahl WA 1993 Cystinosis. In: Pagon R, Bird T, Dolan C, Stephens K, eds. GeneReviews. Seattle: University of Washington. Available at http://www.ncbi.nlm.nih.gov/books/NBK1400/
37. Magen D, Berger L, Coady MJ, Ilivitzki A, Militianu D, Tieder M, Selig S, Lapointe JY, Zelikovic I, Skorecki K 2010 A loss-of-function mutation in NaPi-IIa and renal Fanconi's syndrome. N Engl J Med 362:1102-1109
38. Nafidi O, Lapointe RW, Lepage R, Kumar R, D'Amour P 2009 Mechanisms of renal phosphate loss in liver resection-associated hypophosphatemia. Ann Surg 249:824-827
39. Mayne PD, Kovar IZ 1991 Calcium and phosphorus metabolism in the premature infant. Ann Clin Biochem 28:131-142
40. Laaban JP, Grateau G, Psychoyos I, Laromiguière M, Vuong TK, Rochemaure J 1989 Hypophosphatemia induced by mechanical ventilation in patients with chronic obstructive pulmonary disease. Crit Care Med 17:1115-1120 (Pubitemid 19276532)
41. Roestel C, Hoeping W, Deckert J 2004 Hypophosphatemia in panic disorder. Am J Psychiatry 161:1499-1500
42. Halevy J, Bulvik S 1988 Severe hypophosphatemia in hospitalized patients. Arch Intern Med 148:153-155
43. Schouten BJ, Doogue MP, Soule SG, Hunt PJ 2009 Iron polymaltose- induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem 46:167-169
44. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG 2009 FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 94: 2332-2337
45. Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T 2009 Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 45:814- 816
46. Hothi DK, Harvey E, Piva E, Keating L, Secker D, Geary DF 2006 Calcium and phosphate balance in adolescents on home nocturnal haemodialysis. Pediatr Nephrol 21:835-841 (Pubitemid 43740952)
47. Walton RJ, Bijvoet OLM 1975 Nomogram for derivation of renal threshold phosphate concentration. Lancet 306:309-310
48. Carpenter TO, Mitnick MA, Ellison A, Smith C, Insogna KL 1994 Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. J Clin Endocrinol Metab 78:1378-1383 (Pubitemid 24181008)
49. Rivkees SA, el-Hajj-Fuleihan G, Brown EM, Crawford JD 1992 Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab 75: 1514-1518 (Pubitemid 23001413)
50. Woo VL, Landesberg R, Imel EA, Singer SR, Folpe AL, Econs MJ, Kim T, Harik LR, Jacobs TP 2009 Phosphaturic mesenchymal tumor, mixed connective tissue variant, of the mandible: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 108:925-932
51. Moran M, Paul A 2002 Octreotide scanning in the detection of a mesenchymal tumour in the pubic symphysis causing hypophosphataemic osteomalacia. Int Orthop 26:61-62 (Pubitemid 36055918)
52. Dupond JL, Mahammedi H, Prié D, Collin F, Gil H, Blagosklonov O, Ricbourg B, Meaux-Ruault N, Kantelip B 2005 Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Bone 36:375-378 (Pubitemid 40403835)
53. Hesse E, Moessinger E, Rosenthal H, Laenger F, Brabant G, Petrich T, Gratz KF, Bastian L 2007 Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res 22:158-162 (Pubitemid 46032609)
54. Shulman DI, Hahn G, Benator R, Washington K, White KE, Farber J, Econs MJ 2004 Tumor-induced rickets: usefulness of MR gradient echo recall imaging for tumor localization. J Pediatr 144:381-385 (Pubitemid 38333898)
55. Ward LM, Rauch F, White KE, Filler G, Matzinger MA, Letts M, Travers R, Econs MJ, Glorieux FH 2004 Resolution of severe, adolescent- onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna. Bone 34:905-911 (Pubitemid 38581137)
56. David K, Revesz T, Kratimenos G, Krausz T, Crockard HA 1996 Oncogenic osteomalacia associated with a meningeal phosphaturic mesenchymal tumor. Case report. J Neurosurg 84:288-292
57. Nasu T, Kurisu S, Matsuno S, Tatsumi K, Kakimoto T, Kobayashi M, Nakano Y, Wakasaki H, Furuta H, Nishi M, Sasaki H, Suzuki H, Ito N, Fukumoto S, Nanjo K 2008 Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23. Intern Med 47:957-961 (Pubitemid 351936193)
58. Westerberg PA, Olauson H, Toss G, Wikström B, Morales O, Linde T, Jonsson K, Ljunggren O, Larsson TE 2008 Preoperative tumor localization by means of venous sampling for fibroblast growth factor- 23 in a patient with tumor-induced osteomalacia. Endocr Pract 14:362-367
59. Ito N, Shimizu Y, Suzuki H, Saito T, Okamoto T, Hori M, Akahane M, Fukumoto S, Fujita T 2010 Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia. J Intern Med 268:390-394
60. Takeuchi Y, Suzuki H, Ogura S, Imai R, Yamazaki Y, Yamashita T, Miyamoto Y, Okazaki H, Nakamura K, Nakahara K, Fukumoto S, Fujita T 2004 Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 89:3979-3982 (Pubitemid 39071502)
61. Andreopoulou P, Dumitrescu CE, Kelly MH, Brillante BA, Cutler Peck CM, Wodajo FM, Chang R, Collins MT 2011 Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res 26:1295-1302
62. Reid IR, Murphy WA, Hardy DC, Teitelbaum SL, Bergfeld MA, Whyte MP 1991 X-linked hypophosphatemia: skeletal mass in adults assessed by histomorphometry, computed tomography, and absorptiometry. Am J Med 90:63-69
63. Camp MA, Allon M 1990 Severe hypophosphatemia in hospitalized patients. Miner Electrolyte Metab 16:365-368
64. Zazzo JF, Troché G, Ruel P, Maintenant J 1995 High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function. Intensive Care Med 21:826-831
65. Taylor BE, Huey WY, Buchman TG, Boyle WA, Coopersmith CM 2004 Treatment of hypophosphatemia using a protocol based on patient weight and serum phosphorus level in a surgical intensive care unit. J Am Coll Surg 198:198-204 (Pubitemid 38175234)
66. Clark CL, Sacks GS, Dickerson RN, Kudsk KA, Brown RO 1995 Treatment of hypophosphatemia in patients receiving specialized nutrition support using a graduated dosing scheme: results from a prospective clinical trial. Crit Care Med 23:1504-1511
67. Vannatta JB, Andress DL, Whang R, Papper S 1983 High-dose in- travenous phosphorus therapy for severe complicated hypophosphatemia. South Med J 76:1424-1426 (Pubitemid 14203657)
68. Rosen GH, Boullata JI, O'Rangers EA, Enow NB, Shin B 1995 Intravenous phosphate repletion regimen for critically ill patients with moderate hypophosphatemia. Crit Care Med 23:1204-1210
69. Tenenhouse HS, Econs MJ 2001 Mendelian hypophosphatemias. In: Scriver CR, Beaudet AL, Valle D, Sly WS, Vogelstein B, Childs B, Kinzler KW, eds. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill Professional; 5039-5067
70. Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL 2011 A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 26:1381-1388
71. Harrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK 1985 Healing of bone disease in X-linked hypophosphatemic rickets/ osteomalacia. Induction and maintenance with phosphorus and calcitriol. J Clin Invest 75:1858-1868 (Pubitemid 15237795)
72. Glorieux FH, Marie PJ, Pettifor JM, Delvin EE 1980 Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets.NEngl J Med 303:1023-1031 (Pubitemid 10025213)
73. Lyles KW, Harrelson JM, Drezner MK 1982 The efficacy of vitamin D2 and oral phosphorus therapy in X-linked hypophosphatemic rickets and osteomalacia. J Clin Endocrinol Metab 54:307-315 (Pubitemid 12006602)
74. Balsan S, Tieder M 1990 Linear growth in patients with hypophosphatemic vitamin D-resistant rickets: influence of treatment regimen and parental height. J Pediatr 116:365-371 (Pubitemid 20109787)
75. Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M 1991 Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 325:1843-1848
76. Taylor A, Sherman NH, Norman ME 1995 Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease. Pediatr Nephrol 9:173-175
77. Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ 2010 Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 95:1846-1850
78. Girgis CM, Wong T, Ngu MC, Emmett L, Archer KA, Chen RC, Seibel MJ 2011 Hypophosphataemic osteomalacia in patients on adefovir dipivoxil. J Clin Gastroenterol 45:468-473
79. François H, Coppo P, Hayman JP, Fouqueray B, Mougenot B, Ronco P 2008 Partial Fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. Am J Kidney Dis 51: 298-301
80. Saidenberg-Kermanac'h N, Souabni L, Prendki V, Prie D, Boissier MC 2011 Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease. Joint Bone Spine 78:306-308
81. Bellini E, Pia A, Brizzi MP, Tampellini M, Torta M, Terzolo M, Dogliotti L, Berruti A 2011 Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. Ann Oncol 22:988-990
82. Miller DW, Slovis CM 2000 Hypophosphatemia in the emergency department therapeutics. Am J Emerg Med 18:457-461 (Pubitemid 30471087)
83. Stanga Z, Brunner A, Leuenberger M, Grimble RF, Shenkin A, Allison SP, Lobo DN 2008 Nutrition in clinical practice-the refeeding syndrome: illustrative cases and guidelines for prevention and treatment. Eur J Clin Nutr 62:687-694 (Pubitemid 351803577)